John Libbey Eurotext

European Journal of Dermatology

Sensitivity of cutaneous chronic myelomonocytic leukaemia lesions to hypomethylating treatment Volume 27, issue 5, September-October 2017

Figures

  • Figure 1
Authors
1 Institute of Hematology and Hemato-Oncology Research Centre (CREO),
University of Perugia,
Perugia,
Italy
2 Santo Spirito Hospital,
Pescara,
Department of Hematology,
Bone Marrow Transplant Center,
Pescara,
Italy

Chronic myelomonocytic leukaemia (CMML) is a myelodysplastic/myeloproliferative disorder characterized by monocytosis and single- or multi-lineage dysplasia. Skin infiltration is rare and predicts disease progression or transformation to acute leukaemia [1]. Nearly 60% of CMML patients bear TET2 gene mutations, which are associated with good response to hypomethylating agents (HMA) in myelodysplastic syndromes (MDS) [2]. At present, although HMA are the standard of care for CMML, the overall response [...]